Posts tagged diabetic foot ulcers
Dipexium updates availability of Phase 3 data

Dipexium Pharmaceuticals (NASDAQ:DPRX) updated the status of results from two pivotal Phase 3 clinical trials - OneStep-1 and OneStep-2- of its topical antimicrobial peptide, Locilex, for the treatment of diabetic foot ulcers.

Data tables and listings from both of these trials are currently being produced and evaluated by the company's scientific advisors according to a pre-specified data review procedure. 

Read More
Dipexium completes enrollment in second Phase 3 trial

Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed patient enrollmentin the OneStep-1 pivotal Phase 3 clinical trial of its Locilex broad-spectrum, topical antibiotic peptide.

Last week, the company reached the enrollment objective in the OneStep-2 pivotal trial.

Read More
Dipexium Pharma receives Locilex patent in Japan

Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033.

“We are delighted to receive a Locilex patent in Japan, the third largest pharmaceuticals market in the world,” David Luci, president and CEO, said in a statement.

Read More